Research we fund
The vast majority of funding is raised through partnerships, events and fund raising campaigns and is allocated to a number of programs including research and clinical trial opportunities locally and abroad.
Welcome
The Sydney Blood Cancer Research Institute is a charity which supports laboratory research, clinical research, supportive care research and the provision of specialised care to haematology patients.
What we do
We believe that laboratory research and expansion of our clinical trials for life changing immune therapies and enhancing current therapeutic regimes is the difference that will assist us to gain deeper and further knowledge of blood cancers, advance treatment options and improve outcomes for patients.
News & Research
SBCR Chair Professor Joy Ho awarded the The Carl de Gruchy Oratorship 2022 by the HSANZ.
May 2023 / Read Article
You can help
Support our program of events whether it be through the donation of funds, items for prizes or sponsorship. Our events have grown from strength to strength each year, raising upwards of $ million for research.
Make a Donation
Your kind donation can provide support for research and help advance treatment options and improve outcomes for patients with blood cancer.
Our Research Programs
laboratory Research
Our unit has been heavily involved in the investigation of the immune and molecular pathophysiology of myeloma, and is widely considered an Australian pioneer in examining the immunological basis of myeloma, with enormous impact on current developments in immunotherapy.
Recent work has focused on the precise phenotype of clonal T cells, defining the mode of telomere-independent senescence, with likely implications on the use of CAR-T therapy and other strategies of immunotherapy in myeloma.
immune therapy
RPA Haematology and Sydney Blood Cancer Research has been a pioneer in immunotherapy in Australia.
After being only one of 2 Australian centres in the pivotal trial on chimeric antigen receptor T cells in diffuse large B cell lymphoma (DLBL), we have just completed recruitment of the same therapy in a different lymphoma known as follicular lymphoma.
The clinical trial on DLBL has directly led to registration and provision of the therapy for routine clinical care.
We are initiating similar trials in myeloma, and we have already commenced cutting-edge clinical trials in CAR-T cells derived from donors for the treatment of patients with lymphoma and myeloma. If effective, this therapy which is "off-the-shelf" will hopefully bring additional benefit for patients with life-threatening haematological cancer.
clinical trials
RPA Haematology is one of the highest recruiters of many Australian and multi-national clinical trials in Haematology. Our clinical trial activity covers a wide portfolio - myeloma in all stages of disease, acute myeloid and lymphoblastic leukaemia, acute promyelocytic leukaemia, numerous subtypes of lymphoma.
Supportive care Research
Supportive care is an important aspect of managing people affected by a blood cancer, alongside evidenced based treatment approaches. Supportive to patients and families is undertaken by a multidisciplinary team of health professionals who work together to provide patient centered approach to care.
Our Impact
The Institute of Haematology Research Unit is a leader in both clinical and laboratory research spanning malignant and non-malignant haematology.
Our clinical trials unit has been very active in multiple diseases over many years, investigating and making available many state-of-the-art agents and protocols for our patients.
Our laboratory research unit has concentrated on basic research into the immunology and molecular pathophysiology of myeloma, the molecular basis and monitoring of acute promyelocytic leukaemia and myeloproliferative diseases, the immunological aspects of transplantation and immunotherapy, and the pathophysiology and laboratory assays to monitor the treatment of clotting disorders.
Active Clinical Trials
RPA Haematology is highly active in clinical trials over many years, and is one of the highest recruiters of Australian and multi-national clinical trials in Haematology.
Laboratory research
Australian pioneer in examining the immunological basis of myeloma, with enormous impact on current developments in immunotherapy.
NEW Equipment Purchased
Philanthropic support, particularly from the Mill House Foundation, has enabled the purchase of crucial equipment for our research, including a state of the art Flow Cytometer, a Next generation sequencer and new Biosafety cabinet and cellular incubators .